Strategic partnerships Leverage REGENXBIO’s existing collaboration with AbbVie on ABBV-RGX-314 and explore additional co-development or licensing opportunities in retinal and rare disease gene therapies to expand joint pipeline value.

Clinical momentum Capitalize on positive long-term trial data and ongoing Phase III readouts for sura-vec to position services around late-stage trial support, real-world evidence generation, and regulatory strategy consulting.

Financial runway With a substantial funding position and active public offerings, target capital markets readiness, strategic equity partnerships, and convertible debt opportunities to support pipeline expansion and manufacturing scale.

Manufacturing readiness Offer scalable gene therapy manufacturing, process development, and supply chain optimization to support AAV Therapeutics, given the focus on one-time treatments and the need for reliable, scalable production.

Precision medicine Position data analytics, biomarker development, and patient stratification services to enhance trial design and demonstrate long-term efficacy and safety across retinal and rare disease programs.